Navigation Links
A ray of light on Cardiology

The angiotensin-converting enzyme (ACE) inhibitor ramipril, used for the treatment of hypertension, can retrieve, and may even prevent, left ventricular hypertrophy (LVH), thereby lowering the risk of stroke and myocardial infarction (MI), a new study has shown.Results from the landmark Heat Outcome Prevention Evaluation (HOPE) study showed the drug to cause reversal and prevention of LVH in a broad range of patients – those with normal or controlled blood pressure, both with and without coronary heart disease.//

The HOPE study compared the effects of the ACE inhibitor in addition to standard therapy with placebo and vitamin E in a sample of about 7,580 high-risk patients with cardiovascular disease.In the HOPE sub-study, conducted by Dr James Chadwik and colleagues from the University of Baltimore, the electrocardiograms of 6,222 patients at baseline and at the end of the 4.5 year-long study were compared for the presence, regression or development of LVH. Cardiovascular outcomes such as MI, stroke and heart failure were also evaluated.

Among 92.9 per cent of the patients, ramipril either prevented or caused gradual regression of LVH, independent of its effect on blood pressure control. Adverse cardiovascular outcomes were also lower among those who did not develop LVH or experienced regression of their LVH, compared with those in which LVH developed or did not regress. However, 91 per cent of the patients who received a placebo experienced prevention or regression of LVH, which the researchers said was “intriguing” but was more likely to be due to other risk factor modifications among the study participants.

Since the regression of LVH found with the drug was independent of blood pressure reduction, the study authors suspect that ACE inhibitors have a direct effect in causing regression.Dr Gregory Bosen, professor of cardiovascular medicine at City Hospital in England, agrees that the research raises important issues. Dr Chadw ik said that monitoring changes in LVH status by ECG might predict outcomes for patients with the condition. “We think we can now reduce the risk of cardiovascular events and death by regression of LVH using ECG markers. The ECG is easily applied and relatively inexpensive.”

'"/>




Related medicine news :

1. Doctors operate upon patients in candlelight- latest from the quake scene
2. “Don’t fear long haul flights!” Vascular surgeon tells travelrs
3. Hazards of sunlight
4. Slightly High BP Poses Health Risk
5. Arterial stiffness prevented by light drinking
6. New light on Cardiology
7. Diet, Sunlight connected to Breast Cancer Risk
8. Dangers of sunlight
9. Nightlights could ward diabetic blindness
10. Unborn babies respond to light
11. Sensitive to bright light? You may have sensitive teeth also
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: